Viela Bio (Viela Bio) Interest Coverage : No Debt ⁽¹⁾ (As of Dec. 2020)

View and export this data going back to 2019. Start your Free Trial

What is Viela Bio Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Viela Bio's Operating Income for the three months ended in Dec. 2020 was $-33.73 Mil. Viela Bio's Interest Expense for the three months ended in Dec. 2020 was $0.00 Mil. Viela Bio has no debt. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Viela Bio Inc has no debt.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Viela Bio's Interest Coverage or its related term are showing as below:

VIE's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 138.73
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Viela Bio Interest Coverage Historical Data

The historical data trend for Viela Bio's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Viela Bio Interest Coverage Chart

Viela Bio Annual Data

Trend

Dec18

Dec19

Dec20

Interest Coverage

No Debt

Viela Bio Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
Interest Coverage	Get a 7-Day Free Trial					No Debt	No Debt	N/A	N/A	No Debt

Competitive Comparison of Viela Bio's Interest Coverage

For the Biotechnology subindustry, Viela Bio's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viela Bio's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viela Bio's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Viela Bio's Interest Coverage falls into.

Viela Bio Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Viela Bio's Interest Coverage for the fiscal year that ended in Dec. 2020 is calculated as

Here, for the fiscal year that ended in Dec. 2020, Viela Bio's Interest Expense was $0.00 Mil. Its Operating Income was $-153.88 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Viela Bio had no debt ⁽¹⁾.

Viela Bio's Interest Coverage for the quarter that ended in Dec. 2020 is calculated as

Here, for the three months ended in Dec. 2020, Viela Bio's Interest Expense was $0.00 Mil. Its Operating Income was $-33.73 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Viela Bio had no debt ⁽¹⁾.

The higher the ratio, the stronger the company's Financial Strength is.

Viela Bio (NAS:VIE) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Viela Bio Interest Coverage Related Terms

Thank you for viewing the detailed overview of Viela Bio's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Viela Bio (Viela Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viela Bio Inc (NAS:VIE) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

N/A

Address

One MedImmune Way, First Floor, Area Two, Gaithersburg, MD, USA, 20878

Website

https://www.vielabio.com

Viela Bio Inc is a clinical-stage biotechnology company engaged in developing and commercializing transformative treatments for severe inflammation and autoimmune diseases. Its product inebilizumab, is a humanized monoclonal antibody, designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells.

Executives

Chris Nolet	director	C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Rachelle Suzanne Jacques	director	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Edward Hu	director	10975 TORREY PINES ROAD, LA JOLLA CA 92037
Boyu Capital General Partner Iii, L.p.	10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital General Partner Iii, Ltd.	10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital Group Holdings Ltd.	10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Xyxy Holdings Ltd.	10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital Investment Management Ltd	10 percent owner	SUITE 1501, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boundless Meadow Ltd	10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Xiaomeng Tong	director, 10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Yanling Cao	director, 10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital Fund Iii, L.p.	10 percent owner	C/O MAPLES CORPORATE SERVICES LIMITED BOX 309, UGLAND HOUSE GRAND CAYMAN E9 KYL-1104
Boyu Capital Opportunities Master Fund	10 percent owner	CAYMAN CORPORATE CENTRE 27 HOSPITAL ROAD, GEORGE TOWN CAYMAN ISLANDS E9 KY1-9008
Zhengbin Yao	director, officer: Chief Executive Officer	10301 STELLA LINK ROAD, HOUSTON TX 77025
William Ragatz	officer: VP, Head of Commercial	C/O VIELA BIO, INC., ONE MEDIMMUNE WAY FIRST FLOOR, AREA TWO GAITHERSBURG MD 20878